- Home
- ANET vs AZN Comparison
ANET vs AZN Comparison
Compare ANET & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANET | AZN |
|---|---|---|
| Founded | 2004 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.5B | 250.7B |
| IPO Year | 2014 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ANET | AZN |
|---|---|---|
| Price | $185.78 | $189.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 29 | 12 |
| Target Price | ★ $249.07 | $208.08 |
| AVG Volume (30 Days) | ★ 7.2M | 3.1M |
| Earning Date | 11-03-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $9,005,700,000.00 | N/A |
| Revenue This Year | $48.67 | $7.86 |
| Revenue Next Year | $39.79 | $6.37 |
| P/E Ratio | $57.20 | ★ $31.91 |
| Revenue Growth | ★ 28.60 | N/A |
| 52 Week Low | $114.52 | $87.23 |
| 52 Week High | $217.41 | $212.71 |
Technical Indicators
Market Signals| Indicator | ANET | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 71.08 |
| Support Level | $183.40 | $180.98 |
| Resistance Level | $210.22 | $191.50 |
| Average True Range (ATR) | 8.38 | 3.56 |
| MACD | 0.31 | 1.65 |
| Stochastic Oscillator | 85.66 | 89.65 |
Price Performance
Historical ComparisonAbout ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-fourths of its sales from North America.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.